Octapharma To Build $1.5 Billion Critical Care Manufacturing Facility In South Carolina

Octapharma plans to invest $1.5 billion in its first U.S.-based manufacturing and production facility, creating approximately 1,500 full-time jobs in Rock Hill, South Carolina.

The 50-acre campus will be developed at Palmetto Research Park and is expected to become one of the largest private biomedical investments in South Carolina’s history.

The facility will produce plasma-derived therapies from Octapharma’s portfolio, establishing domestic manufacturing capabilities for medicines currently supported by the company’s international production network.

Octapharma also plans to manufacture bleeding management and trauma care products used for national security and emergency preparedness purposes.

The project is intended to reduce dependence on overseas pharmaceutical supply chains while bringing production closer to the plasma donated in the United States and the American patients who rely on the company’s treatments.

Octapharma selected Rock Hill following a planning and zoning process conducted with Rock Hill and York County officials and in coordination with local, state and federal leaders.

The company cited South Carolina’s advanced manufacturing infrastructure, logistics network, access to deep-water ports and growing biomedical workforce as factors supporting the location decision.

Octapharma expects demand for its existing therapies and future products to increase, requiring the company to expand its manufacturing capacity.

Construction and groundbreaking details will be announced at a later date.

Headquartered in Lachen, Switzerland, Octapharma develops and manufactures human protein therapies derived from human plasma and cell lines. The company has more than 11,000 employees and serves patients in 117 countries across immunotherapy, hematology and critical care.

Octapharma currently operates five European manufacturing facilities, seven research and development sites and more than 200 plasma donation centers across the United States and Europe.

KEY QUOTES:

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our U.S. manufacturing facility will be an important milestone. From a U.S. national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

Wolfgang Marguerre, CEO and Chairman of Octapharma

“We have built a significant presence in the U.S. over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centers. As the demand in the U.S. for our portfolio of products continues to grow, the new U.S. manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the U.S. and to the patients who rely on them.”

Tobias Marguerre, Deputy Chairman of Octapharma

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition. We also want to thank Governor McMaster and South Carolina’s federal and state delegation for their support in welcoming Octapharma to the Palmetto State.”

“South Carolina’s talented workforce, strong life sciences ecosystem and pro-business environment made it clear this was the right home for our first U.S. manufacturing facility.”

Flemming Nielsen, President of Octapharma USA

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Source link

Octapharma To Build $1.5 Billion State-Of-The-Art Critical Care Manufacturing Facility In Rock Hill, SC

Octapharma, the largest privately owned and independent plasma fractionator in the world, has formally announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina, making it one of the largest private biomedical investments in the state’s history.

Once operations commence, the facility will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while complementing the company’s global manufacturing capabilities. The Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs. The announcement follows a thorough planning and zoning process coordinated with officials from Rock Hill and York County, alongside local, state, and federal leaders.

Rock Hill was selected for its proven infrastructure for advanced manufacturing, access to deep-water ports, and proximity to major logistics networks. South Carolina’s pipeline of biomedical and life sciences talent, supported by technical colleges and universities, is expected to provide the workforce needed to support the facility. Octapharma has built a significant US presence over the past 20 years through its commercial capabilities and extensive network of plasma donation centers, and the new site is intended to bring production of its FDA-approved therapies closer to both the plasma donated in the US and the patients who rely on them.

Octapharma is headquartered in Lachen, Switzerland, with more than 11,000 employees serving patients in 117 countries across Immunotherapy, Hematology, and Critical Care. The company operates 190 plasma donation centers across the United States and seven R&D sites and five manufacturing facilities in Europe. More details regarding a groundbreaking ceremony and construction timeline will be released at a later date.

KEY QUOTES:

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products. Our manufacturing capacity must evolve to support this ambition, and our US manufacturing facility will be an important milestone. From a US national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

Wolfgang Marguerre, CEO and Chairman, Octapharma

“We have built a significant presence in the US over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centres. As the demand in the US for our portfolio of products continues to grow, the new US manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the US, and to the patients who rely on them.”

Tobias Marguerre, Deputy Chairman, Octapharma

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition. South Carolina’s talented workforce, strong life sciences ecosystem, and pro-business environment made it clear this was the right home for our first US manufacturing facility.”

Flemming Nielsen, President, Octapharma USA

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Source link

Octapharma to build $1.5 billion state-of-the-art critical care manufacturing facility in Rock Hill, SC

New 50-acre campus will be one of the largest private biomedical investments in state’s history, bringing 1,500 jobs to South Carolina

Manufacturing facility will establish domestic production of Octapharma’s plasma-based therapies and products of national security concern, reducing dependency on overseas supply chains

PARAMUS, N.J., July 29, 2026 /PRNewswire/ — Octapharma, the largest privately owned and independent plasma fractionator in the world, has formally announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina, making this one of the largest private biomedical investments in the state’s history.  

Once operations commence, this facility will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while also complementing the company’s global manufacturing capabilities. Octapharma’s Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs.

Today’s announcement follows a thorough planning and zoning process coordinated with officials from Rock Hill and York County, and close partnership with local, state and federal leaders. 

“We expect significant future growth, driven by our existing life-saving therapies and a strong pipeline of new products,” said Wolfgang Marguerre, CEO and Chairman, Octapharma. “Our manufacturing capacity must evolve to support this ambition, and our US manufacturing facility will be an important milestone. From a US national security perspective, having the ability to produce and supply our therapies domestically is invaluable.”

“We have built a significant presence in the US over the last 20 years through our commercial capabilities, alongside our extensive network of plasma donation centres,” said Tobias Marguerre, Deputy Chairman, Octapharma. “As the demand in the US for our portfolio of products continues to grow, the new US manufacturing site will bring production of our FDA-approved therapies closer to both the plasma donated in the US, and to the patients who rely on them.”

Octapharma’s Commitment to Rock Hill
South Carolina’s leadership and Octapharma share a commitment to biomedical innovation, domestic supply chain resilience, and long-term economic investment in the surrounding community. 

With its proven infrastructure for advanced manufacturing, access to deep-water ports and proximity to major logistics networks, Rock Hill was selected as an ideal location for Octapharma’s first US facility. Additionally, South Carolina’s strong pipeline of biomedical and life sciences talent, supported by top-tier technical colleges and universities, will provide the workforce needed to support clean, efficient biopharmaceutical manufacturing at scale.

“Octapharma appreciates the good-faith work of every elected official and staff member in York County and Rock Hill who helped bring this to fruition,” said Flemming Nielsen, President, Octapharma USA. “We also want to thank Governor McMaster and South Carolina’s federal and state delegation for their support in welcoming Octapharma to the Palmetto State. South Carolina’s talented workforce, strong life sciences ecosystem, and pro-business environment made it clear this was the right home for our first US manufacturing facility.” 

More details regarding a groundbreaking ceremony and construction timeline will be released at a later date.  

To view the full release from the South Carolina Department of Commerce, please click here.  

About Octapharma
Octapharma is one of the world’s largest human protein manufacturers, developing and producing therapies from human plasma and human cell lines. Headquartered in Lachen, Switzerland, Octapharma has over 11,000 employees and serves patients in 117 countries across Immunotherapy, Hematology, and Critical Care. Octapharma has 190 plasma donation centers across the United States 

With seven R&D sites, five manufacturing facilities in Europe, and more than 200 plasma donation centers in the US and Europe, Octapharma has delivered trusted therapies for over 40 years. The company is committed to improving lives through innovation, quality, and a deep focus on patient care and clinical partnership. To learn more please visit www.octapharma.com. 

Media Contact:
Michael Steier
[email protected]
+1 (551) 410-7797

SOURCE Octapharma

Source link

Ukraine plans to build a drone manufacturing plant in the United States.

Kyiv, Ukraine – Ukrainian President Volodymyr Zelenskyy announced that his country intends to establish a drone manufacturing plant in the United States, a move aimed at strengthening defense cooperation between Kyiv and Washington and increasing production capacity to meet the needs of the Ukrainian armed forces.

Zelenskyy explained that the project is part of a broader strategy to develop Ukraine’s military industries in partnership with its allies, noting that drones have become a crucial element in modern military operations, especially given the ongoing conflict with Russia.

He added that establishing the plant will accelerate the production of advanced military technologies and facilitate the exchange of expertise with American companies, thereby enhancing Ukraine’s ability to address battlefield challenges and develop defensive and offensive systems using drones.

The announcement comes as the United States continues to provide military and logistical support to Ukraine, amid efforts to strengthen defense industry cooperation between the two countries, ensuring a sustained supply of necessary military equipment in the coming phase.

Observers believe the project reflects the growing strategic partnership between Kyiv and Washington and underscores the increasing importance of drones in modern conflicts, particularly as the Russian-Ukrainian war continues and enters a phase heavily reliant on advanced military technology.

Source link

Trump says tariffs pushed Korean, Japanese and German automakers to build U.S. plants

The U.S. president said tariffs pushed Korean, Japanese and German automakers to expand American production as he renewed his manufacturing agenda.

U.S. President Donald Trump speaks at a lunch in the White House Rose Garden on July 6.
AP/YONHAP

U.S. President Donald Trump reiterated Monday that his tariff policy has driven Korean, Japanese and German automakers to build their factories in the United States, as his administration has been using duties to restore American manufacturing.

Trump made the remarks during a White House event celebrating the launch of “Trump Accounts,” new investment accounts for children.

“We’ve never built as many automobile plants. They are all over, and they are coming from all over the world. You know why? Because they don’t want to pay tariffs. If they build their cars here, they pay no tariffs,” he said.

“So Japan, instead of making them in Japan […] or South Korea […] instead of making them in Germany […] They are all building plants here now.”

Since his return to the White House last year, Trump has been leveraging tariffs as a key policy tool to revitalize the United States’ manufacturing, increase foreign investment and reduce trade deficits.

Amid Trump’s tariff pressure, Korean conglomerate Hyundai Motor Group announced last year that it would invest $26 billion in the United States through 2028.

On Iran, Trump said that the United States will either make a deal with the Islamic Republic or “finish the job,” stressing that the United States “will win one way or the other.”

“It won’t be tough to finish the job. I would rather make a deal because I don’t want to affect 91 million people,” he said. “We can knock down their bridges in one hour. We can knock out their energy supply.”

Commenting on the Russia-Ukraine war, Trump said that both Moscow and Kyiv want to end the war. He also voiced optimism, saying, “I think we are getting much closer [to ending the war] than people realize.”

“I think [Putin] does feel pressure. He wants to end it and Ukraine wants to end it, and we are in talks, and we will see if we can get it ended.”

Trump plans to have bilateral talks with Ukrainian President Volodymyr Zelenskyy on the margins of the North Atlantic Treaty Organization summit set to take place in Ankara, Turkey, on Tuesday and Wednesday.

Yonhap

Source link

Apparel Brands Partner With Unspun to Build Automated U.S. Manufacturing Hub » World Business Outlook

Leading brands, including Walmart, have signed letters of support for unspun’s plan to build domestic manufacturing capacity in the U.S. using an AI-enabled 3D weaving technology designed to bring apparel manufacturing closer to consumers at a commercial scale. Supply chain partners Bethel Industries, Peckham, and PDS Ltd / GSC Link are also participating to help establish automated domestic production hubs, with initial production on the near-term horizon.

With more than USD 50M in VC funding, unspun is advancing its proprietary 3D weaving technology — an AI-enabled system that produces garments directly from yarn via a highly automated process. REI has also signed a letter of support for the initiative, reinforcing broad industry demand for reshored, next-generation apparel manufacturing. unspun has equipment ready for deployment and is currently evaluating sites across multiple states.

“We are not exploring whether domestic apparel manufacturing can work. We are building it,” said Arne Arens, CEO of unspun and former Global Brand President of The North Face. “Our clients are looking for a new production model because they see the economics: manufacturing closer to the customer, responding to demand within the same season, and creating skilled American jobs in the process.”

Unspun (Logo credit: Business Wire)

unspun’s 3D technology weaves semi-finished garments directly from yarn in minutes, transforming dozens of traditional cut-and-sew steps into a single, automated process. The platform enables brands to produce closer to demand, reorder within the same season, and significantly reduce excess inventory — an issue that costs the industry billions each year. By shortening production timelines from months to days, 3D weaving can improve gross margins by 400–500 basis points through fewer markdowns and write-offs, while also supporting the creation of skilled manufacturing jobs in the U.S. This approach is designed to unlock domestic, demand-driven production at commercial scale as the apparel industry shifts toward next-generation manufacturing systems.

Avisnash Bhasker, Vice President, Apparel Production Development at Walmart, said, “Our customers are proud to buy apparel made in America, and the demand keeps growing. We are excited about unspun’s commitment and effort in helping rebuild domestic manufacturing capability that is faster, smarter, and designed for how customers actually shop.”

unspun is currently evaluating potential locations, infrastructure requirements, and workforce training programs as it moves toward establishing the first automated apparel manufacturing hubs in the United States powered by 3D weaving technology. The initiative represents one of the first examples of AI-enabled automation being deployed to rebuild domestic manufacturing capacity at scale.

Arens was appointed CEO in March 2026, bringing decades of experience leading global consumer brands, including The North Face and Boardriders, the parent company of Quicksilver and Billabong. His appointment signaled unspun’s shift from technology development to industrial-scale deployment.

Source

Source link

U.S. and allies move to build missiles and drones closer to Asia’s flashpoints

A U.S.-led defense manufacturing partnership agreed ⁠to launch a new missile motor production program with Japan, push forward a drone cooperation effort across Asia and explore building a new ammunition production line in the Philippines, the Pentagon ​said on Friday.

The Partnership for Indo-Pacific Industrial Resilience, known ‌as PIPIR, ‌is a group of nations working ​together to build up their weapons and defense manufacturing capacity in the Asia-Pacific region. The United States set it ⁠up in May 2024 to reduce supply chain risks and help ⁠allies produce and maintain military equipment closer to where it might be needed.

The Pentagon published a ​joint statement following ⁠a virtual meeting on Wednesday, where the group welcomed two new members — Thailand and the ⁠United Kingdom — bringing ​its total membership to 16 countries spanning ​both the Indo-Pacific and Europe.

The group said ​it had ‌agreed to set up a new program to produce solid rocket motors — the propulsion systems used in many guided weapons — with Japan taking the lead. The ‌move is seen as a way to boost production capacity outside the United States for a key weapons component.

On drones, members agreed on a series of steps to develop common ​standards ​and shared supply chains for small military drones ​across the region, including work on batteries and small motors ⁠that power them. The group also agreed to explore building drones together across a range of military uses.

On ammunition, members said they would look into ​the Philippines hosting a new facility to load, assemble, and package 30mm cannon rounds — a type of ammunition widely used by military aircraft and ground vehicles.

Source link